Compugen’s COM503 Advances with FDA Nod and Gilead Deal
Company Announcements

Compugen’s COM503 Advances with FDA Nod and Gilead Deal

Compugen (CGEN) has released an update.

Compugen Ltd. has announced FDA clearance for their Phase 1 trial of COM503, a potential new cancer treatment for solid tumors, slated to begin in Q4 2024. This clearance has resulted in a $30 million milestone payment from Gilead Sciences, as part of a larger licensing agreement that could ultimately be worth up to $848 million. The company is optimistic about the antibody’s unique approach to harnessing cytokine biology and is well-funded to continue development activities into 2027.

For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCompugen Showcases Promising Data on Ovarian Cancer Therapy
TheFlyCompugen management to meet with Oppenheimer
TipRanks Auto-Generated NewsdeskCompugen Shareholders Approve All Proposals
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App